What is the recommended dose of oral corticosteroids for durvalumab‑induced pneumonitis?

Corticosteroid Dosing for Durvalumab-Induced Pneumonitis

For grade 2 durvalumab-induced pneumonitis, initiate oral prednisone at 1 mg/kg/day (or equivalent); for grade 3 or higher, use intravenous methylprednisolone at 1-2 mg/kg/day. 1

Grade-Based Treatment Algorithm

Grade 2 (Symptomatic, not limiting ADLs)

• Start oral prednisone 1 mg/kg/day (or equivalent corticosteroid) 1
• Taper over 6 weeks after improvement to grade <1 1
• Recent evidence from a 2026 randomized trial demonstrates that a 6-week taper is superior to a 3-week taper, with treatment success rates of 85.2% vs 66.7% 2
• The 6-week regimen is now the evidence-based standard 2

Grade 3 or Higher (Severe, limiting self-care)

• Start IV methylprednisolone 1-2 mg/kg/day (or equivalent) 1
• Taper over 6-8 weeks after improvement to grade <1 1
• More aggressive initial dosing is warranted for severe cases

Critical Management Points

Steroid-Refractory Disease (No improvement within 48-72 hours)

If pneumonitis doesn't improve after 72 hours of corticosteroids, escalate to second-line immunosuppression 3, 1:

• Tocilizumab 8 mg/kg (repeat every 2 weeks if needed)
• Infliximab 5 mg/kg (repeat every 2 weeks if needed)
• IVIG 2 g/kg over 2-5 days
• Alternative options: mycophenolate mofetil 1g twice daily or cyclophosphamide

Durvalumab-Specific Considerations

Durvalumab-induced pneumonitis frequently requires extended taper durations beyond 12-17 weeks to achieve stable remission 4. Meta-analysis data shows that approximately 25.8% of patients relapse after corticosteroid treatment, with fixed short-term tapers associated with significantly higher recurrence risk 4. This is particularly important for durvalumab compared to other checkpoint inhibitors.

Risk Factors Requiring Vigilance

• Higher mean lung radiation dose increases pneumonitis risk (OR 4.73) 5
• Pre-existing COPD increases risk (OR 2.60) 5
• These patients may need more aggressive initial treatment and longer tapers

Common Pitfalls to Avoid

1. Premature taper: The 3-week taper previously used in some centers is inadequate—stick to the 6-week minimum for grade 2 2

2. Inadequate initial dosing: Don't underdose—use the full 1 mg/kg/day for grade 2 or 1-2 mg/kg/day IV for grade 3+ 1

3. Missing infectious co-triggers: Rule out concurrent viral infections (like human metapneumovirus) that can synergize with immune-mediated injury 6. Obtain comprehensive microbiologic workup including multiplex molecular testing

4. Rigid taper schedules: While 6 weeks is the evidence-based minimum, some patients—especially those on durvalumab—require individualized extension to 12-17+ weeks based on clinical response 4. Monitor closely for recurrence during taper

5. Delayed escalation: If no improvement by 72 hours, don't wait—add second-line agents 1

Durvalumab Discontinuation

Permanently discontinue durvalumab for grade 2 or higher pneumonitis 3, 6. The risk of recurrence with rechallenge is substantial, though some guidelines suggest rechallenge may be considered for grade 2 only after complete resolution with close monitoring 1.